174 related articles for article (PubMed ID: 28814738)
1. Identification of Novel Non-secosteroidal Vitamin D Receptor Agonists with Potent Cardioprotective Effects and devoid of Hypercalcemia.
Khedkar SA; Samad MA; Choudhury S; Lee JY; Zhang D; Thadhani RI; Karumanchi SA; Rigby AC; Kang PM
Sci Rep; 2017 Aug; 7(1):8427. PubMed ID: 28814738
[TBL] [Abstract][Full Text] [Related]
2. Nongenomic effects of 1α,25-dihydroxyvitamin D
Hirota Y; Nakagawa K; Mimatsu S; Sawada N; Sakaki T; Kubodera N; Kamao M; Tsugawa N; Suhara Y; Okano T
Biochem Biophys Res Commun; 2017 Jan; 483(1):359-365. PubMed ID: 28025137
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.
Chen B; Kawai M; Wu-Wong JR
Bioorg Med Chem Lett; 2013 Nov; 23(21):5949-52. PubMed ID: 24035340
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
Wu-Wong JR; Chen YW; Wessale JL
Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
[TBL] [Abstract][Full Text] [Related]
5. The vitamin D receptor functions as a transcription regulator in the absence of 1,25-dihydroxyvitamin D
Lee SM; Pike JW
J Steroid Biochem Mol Biol; 2016 Nov; 164():265-270. PubMed ID: 26323657
[TBL] [Abstract][Full Text] [Related]
6. The vitamin D3 1alpha-hydroxylase gene and its regulation by active vitamin D3.
Takeyama K; Kato S
Biosci Biotechnol Biochem; 2011; 75(2):208-13. PubMed ID: 21307571
[TBL] [Abstract][Full Text] [Related]
7. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
8. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
[TBL] [Abstract][Full Text] [Related]
9. A High-Calcium and Phosphate Rescue Diet and VDR-Expressing Transgenes Normalize Serum Vitamin D Metabolite Profiles and Renal Cyp27b1 and Cyp24a1 Expression in VDR Null Mice.
Kaufmann M; Lee SM; Pike JW; Jones G
Endocrinology; 2015 Dec; 156(12):4388-97. PubMed ID: 26441239
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. The vitamin D receptor in the proximal renal tubule is a key regulator of serum 1α,25-dihydroxyvitamin D₃.
Wang Y; Zhu J; DeLuca HF
Am J Physiol Endocrinol Metab; 2015 Feb; 308(3):E201-5. PubMed ID: 25425001
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the murine renal vitamin D receptor by 1,25-dihydroxyvitamin D3 and calcium.
Healy KD; Zella JB; Prahl JM; DeLuca HF
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9733-7. PubMed ID: 12900504
[TBL] [Abstract][Full Text] [Related]
13. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.
Segersten U; Holm PK; Björklund P; Hessman O; Nordgren H; Binderup L; Akerström G; Hellman P; Westin G
Breast Cancer Res; 2005; 7(6):R980-6. PubMed ID: 16280049
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
[TBL] [Abstract][Full Text] [Related]
15. Novel nonsecosteroidal VDR ligands with phenyl-pyrrolyl pentane skeleton for cancer therapy.
Ge Z; Hao M; Xu M; Su Z; Kang Z; Xue L; Zhang C
Eur J Med Chem; 2016 Jan; 107():48-62. PubMed ID: 26562542
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators.
Ma Y; Khalifa B; Yee YK; Lu J; Memezawa A; Savkur RS; Yamamoto Y; Chintalacharuvu SR; Yamaoka K; Stayrook KR; Bramlett KS; Zeng QQ; Chandrasekhar S; Yu XP; Linebarger JH; Iturria SJ; Burris TP; Kato S; Chin WW; Nagpal S
J Clin Invest; 2006 Apr; 116(4):892-904. PubMed ID: 16528410
[TBL] [Abstract][Full Text] [Related]
17. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3).
Bareis P; Kállay E; Bischof MG; Bises G; Hofer H; Pötzi C; Manhardt T; Bland R; Cross HS
Exp Cell Res; 2002 Jun; 276(2):320-7. PubMed ID: 12027461
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.
Roberts JM; Martin RS; Piyarathna DB; MacKrell JG; Rocha GV; Dodge JA; Coarfa C; Krishnan V; Rowley DR; Weigel NL
Oncotarget; 2017 Jul; 8(27):44447-44464. PubMed ID: 28591703
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
20. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
